MB-1Homo sapiens (Human)Cancer cell line
Also known as: MB1
🤖 AI SummaryBased on 1 publications
Quick Overview
Human anaplastic thyroid cancer cell line for targeted therapy research.
Detailed Summary
The MB-1 cell line is a human anaplastic thyroid cancer (ATC) cell line established from a 57-year-old male patient with thyroid cancer and neutrophilia. It is used in preclinical studies to investigate targeted therapies, including BRAF kinase inhibitors and proteasome inhibitors. Research has shown that MB-1 cells exhibit resistance to sorafenib but show some response to bortezomib, leading to temporary tumor growth inhibition. The cell line has a complex karyotype with multiple chromosomal abnormalities, and it retains the immunophenotypic characteristics of the original tumor. MB-1 is valuable for studying ATC biology and evaluating novel therapeutic strategies.
Research Applications
Targeted therapy researchPreclinical drug testingCancer biology studies
Key Characteristics
Human originAnaplastic thyroid cancerComplex karyotypeResistant to sorafenibResponsive to bortezomib
Generated on 6/18/2025
Basic Information
| Database ID | CVCL_2109 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Thyroid gland[UBERON:UBERON_0002046] |
Donor Information
| Age | 57 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Anaplastic thyroid carcinoma |
|---|---|
| Lineage | Thyroid |
| Subtype | Anaplastic Thyroid Cancer |
| OncoTree Code | THAP |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-001356_source |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
11
D13S317
11
D16S539
11
D18S51
19
D19S433
15
D21S11
31
D2S1338
20
D3S1358
14
D5S818
10
D7S820
9
D8S1179
13
FGA
23
Penta D
15
Penta E
13
TH01
9
TPOX
11
vWA
14
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...